Selected Podcast

EP 1120B - Prompt Recognition & Treatment Found Effective for Lung Disease Patients Who Receive New Drug

A diagnosis of lung cancer used to be a diagnosis of death. Not anymore.

Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open in August 2022.

Using data from nine clinical trials, this study provides one of the most comprehensive analyses of interstitial lung disease diagnosis and treatment in patients who received an antibody-drug conjugate known as T-DXd, from a class of drugs designed as a targeted therapy for treating cancers.

The retrospective review examined 1,150 heavily pre-treated patients with breast, lung, gastric, colorectal, or other cancers across nine studies treated with T-DXd, also known as ENHERTU®.

Senior author Charles Powell, MD, MBA, joins us today to discuss the findings. He is the Professor of Medicine and System Division Chief for Pulmonary, Critical Care, and Sleep Medicine at the Icahn School of Medicine at Mount Sinai in New York and the Medical Director of Respiratory Therapy at Mount Sinai Hospital.  He also directs research programs focused on the early detection of lung interstitial disease and airway disease.
EP 1120B - Prompt Recognition & Treatment Found Effective for Lung Disease Patients Who Receive New Drug
Featuring:
Dr. Charles Powell, MD, MBA
Dr. Charles A. Powell is Professor of Medicine and System Division Chief for Pulmonary, Critical Care and Sleep Medicine at the Icahn School of Medicine at Mount Sinai in New York and Medical Director of Respiratory Therapy at Mount Sinai Hospital.  He received his medical degree at University of Chicago and trained in Internal Medicine at Columbia University and in Pulmonary and Critical Care Medicine at Boston University.  A primary focus of Dr. Powell’s research and clinical activities is lung cancer.  He also directs research programs focused on early detection of lung interstitial disease and airways disease.  Dr. Powell is NIH funded,  has published over 100 articles, and directs a NIH funded laboratory that examines the genomics of lung cancer and lung fibrosis.  He was the founding chair of the ATS Assembly on Thoracic Oncology and he sees patients in consultation regarding lung nodules and lung cancer.  Dr. Powell’s International Reputation in the field is demonstrated by his election as President of the Fleischner Society.  Dr. Powell is the CEO of the Mount Sinai-National Jewish Health Respiratory Institute that is a partnership of The Icahn School of Medicine at Mount Sinai, a top ranked academic medical center in New York City, and National Jewish Health, the nation’s leading respiratory hospital based in Denver, Colorado. Combining the strengths of both entities into an integrated Respiratory Institute brings together leading expertise in diagnosing and treating all forms of respiratory illness and lung disease, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and bronchiectasis. Through the integration of research advances, clinical skill and patient-focused processes and protocols, the Respiratory Institute offers a model for the state-of-the- art delivery of multidisciplinary, outcomes-driven care, and for the application of precision medicine for the treatment of respiratory disease.